Document is current

Article History

Received: 24 May 2024

Accepted: 16 July 2024

First Online: 5 August 2024

Declarations

:

: Fraser W Gibb reports speaker and advisory board fees from Abbott. Anna Strzelecka reports speaker fees from Astra Zeneca, Boehringer, Ingelheim, Janssen, Lilly, MSD, Novo Nordisk, Napp and Menarini. Karen A Adamson, James McLaren, Thinzar Min, Hermione Price and Sailesh Sankaranarayanan report no relevant disclosures.

: In the United Kingdom, the Medical Research Council and the NHS Health Research Authority has a decision tool to determine if Research Ethics Committee (REC) approval is required (hra-decisiontools.org.uk). After following the required steps, REC approval was deemed to be not required based on the retrospective and non-interventional nature of the study. This study was submitted through the UK Integrated Research Application System (IRAS) and approved by the Health Research Authority/ Health Care Research Wales (reference 22/NRS/0022), Health and Social Care in Northern Ireland (reference NT22-31330-06) and NHS Research Scotland (reference 22/PR/0456). Due to the non-interventional and retrospective nature of the study with no active involvement required from participants, consent was not required. All data were anonymised and handled in accordance with General Data Protection Regulation requirements.